BBOT BridgeBio Oncology Therapeutics, Inc.

NASDAQ
$4.66

BridgeBio Oncology Therapeutics, Inc. (BBOT) Hedge Fund Activity

This view isolates hedge funds from the broader institutional ownership shown on the Institutional tab. A pension fund tracking an index may have no view on a stock; when a hedge fund builds or exits a position, that decision can carry information. This page measures those changes. Positions as of June 30, 2026.

Based on quarterly 13F long-equity filings. Changes compare reported quarter-end positions; filings can be reported up to 45 days later and do not represent a fund's complete exposure.

Hedge fund breadth
-37.50
5 buyers / 11 sellers
STRONG SELLING
Funds compared
20
funds with comparable BBOT positions
12 current holders · 18 prior-quarter holders
Net share change
-897.6K
+637.7K added, -1.54M cut
Position activity
2 new 3 increased 3 reduced 8 exited

Most significant moves

Ranked by conviction, not size — how much of the fund's own book the position represents, how far it moved, and what kind of fund made it.

Fund Action Shares changed Change Est. value Portfolio wt. Score
Paradigm BioCapital Advisors Growth Healthcare Sold Out -868.2K -100.0% $6.6M 0.0% 62
TWO SIGMA INVESTMENTS, LP Quant New +26.5K $201.8K 0.0% 57
Qube Research & Technologies Ltd Quant Sold Out -71.9K -100.0% $548.1K 0.0% 55
Woodline Partners LP Long/Short Sold Out -103.7K -100.0% $790.2K 0.0% 54
Hudson Bay Capital Management Event Sold Out -110.0K -100.0% $838.2K 0.0% 53
Quadrature Capital Quant Sold Out -13.4K -100.0% $101.7K 0.0% 52
ExodusPoint Capital Management Long/Short Quant Sold Out -48.1K -100.0% $366.7K 0.0% 52
Schonfeld Strategic Advisors Long/Short Quant New +11.5K $87.7K 0.0% 51
Boothbay Fund Management Sold Out -80.9K -100.0% $616.3K 0.0% 49
Aquatic Capital Management Quant Sold Out -11.8K -100.0% $89.9K 0.0% 48

Most significant buyers

By move score, not size.

  • TWO SIGMA INVESTMENTS, LP New · +26.5K
  • Schonfeld Strategic Advisors New · +11.5K
  • Brevan Howard Capital Management Increased · +74.6K
  • Armistice Capital Increased · +436.0K
  • CITADEL ADVISORS LLC Increased · +89.1K

Most significant sellers

By move score, not size.

  • Paradigm BioCapital Advisors Sold Out · -868.2K
  • Qube Research & Technologies Ltd Sold Out · -71.9K
  • Woodline Partners LP Sold Out · -103.7K
  • Hudson Bay Capital Management Sold Out · -110.0K
  • Quadrature Capital Sold Out · -13.4K

Hedge fund positions

Fund Tier Shares Previous Change Change % Portfolio wt. Action Score
Paradigm BioCapital Advisors 1 0 868.2K -868.2K -100.0% 0.0% Sold Out 62
TWO SIGMA INVESTMENTS, LP 2 26.5K 0 +26.5K 0.0% New 57
Qube Research & Technologies Ltd 2 0 71.9K -71.9K -100.0% 0.0% Sold Out 55
Woodline Partners LP 2 0 103.7K -103.7K -100.0% 0.0% Sold Out 54
Hudson Bay Capital Management 3 0 110.0K -110.0K -100.0% 0.0% Sold Out 53
Quadrature Capital 3 0 13.4K -13.4K -100.0% 0.0% Sold Out 52
ExodusPoint Capital Management 3 0 48.1K -48.1K -100.0% 0.0% Sold Out 52
Schonfeld Strategic Advisors 3 11.5K 0 +11.5K 0.0% New 51
Boothbay Fund Management 4 0 80.9K -80.9K -100.0% 0.0% Sold Out 49
Aquatic Capital Management 4 0 11.8K -11.8K -100.0% 0.0% Sold Out 48
Brevan Howard Capital Management 3 88.9K 14.2K +74.6K +523.9% 0.0% Increased 43
MILLENNIUM MANAGEMENT LLC 2 105.5K 266.0K -160.5K -60.3% 0.0% Reduced 43
RENAISSANCE TECHNOLOGIES LLC 1 58.6K 101.9K -43.3K -42.5% 0.0% Reduced 38
Squarepoint Ops LLC 2 19.7K 43.2K -23.5K -54.5% 0.0% Reduced 37
Armistice Capital 3 1.8M 1.3M +436.0K +32.8% 0.4% Increased 34
CITADEL ADVISORS LLC 1 2.6M 2.5M +89.1K +3.5% 0.0% Increased 28
Deerfield Management 1 4.9M 4.9M 0 +0.0% 0.5% Unchanged 28
EcoR1 Capital 2 2.8M 2.8M 0 +0.0% 1.1% Unchanged 24
ADAGE CAPITAL PARTNERS GP, L.L.C. 2 400.0K 400.0K 0 +0.0% 0.0% Unchanged 20
Moore Capital Management 3 100.0K 100.0K 0 +0.0% 0.0% Unchanged 16

Every fund above opens. Subscribers can see any manager's whole portfolio — every position, its weight, and what they bought, trimmed and exited last quarter.

Sign in or subscribe

Hedge funds are identified from their 13F filings, which are due 45 days after quarter end and cover long U.S.-listed equity positions only. A fund's short book never appears, so a reduced position can mean a changed view or a changed hedge — the filing doesn't say which.